- Acquired by BioLineRx, Oct 2018
About
Biokine Therapeutics is a private biopharmaceutical company focused on identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis, and developing therapeutics against these diseases. The company's lead product, BKT140/BL8040, is a high-affinity, long-acting CXCR4 receptor inhibitor. It has been developed for indications such as stem cell mobilization and immunotherapy for cancer. Biokine has also developed unique technologies like MigHit™ and ImmunHit™ for identifying small molecules targeting cancer pathways. Biokine's lead product, BL-8040 (BKT-140) is co-developed with BioLineRx (NASDAQ:BLRX) for multiple indications, including: Stem Cell Mobilization (Phase 3), AML (Phase 2b), Pancreatic Carcinoma in combination with Chemo and anti-PD-1/KEYTRUDA (Phase 2a).
Offices
Q&A
- What is Biokine Therapeutics' primary focus?
- Biokine Therapeutics is a private biopharmaceutical company focused on identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis, and developing therapeutics against these diseases. Their lead product, BKT140/BL8040, is a high-affinity, long-acting CXCR4 receptor inhibitor.
- When was Biokine Therapeutics founded?
- Biokine Therapeutics was founded in July 2000.
- How many employees does Biokine Therapeutics currently have?
- Biokine Therapeutics has 1-10 employees.
- What is the status of Biokine Therapeutics?
- Biokine Therapeutics was acquired by BioLineRx in October 2018.
- What was Biokine Therapeutics' most recent funding round?
- Biokine Therapeutics received a Debt Financing round in 2018. Lead investors included Kreos Capital and Clal Biotechnology Industries.
- What is Biokine Therapeutics' total funding raised to date?
- Biokine Therapeutics has raised a total of $1,950,000 USD.
- What is the lead product of Biokine Therapeutics?
- The lead product of Biokine Therapeutics is BKT140/BL8040, a high-affinity, long-acting CXCR4 receptor inhibitor, co-developed with BioLineRx.
- What are the primary indications for Biokine Therapeutics' lead product?
- Biokine Therapeutics' lead product, BL-8040 (BKT-140), is being developed for indications such as stem cell mobilization, AML (Phase 2b), and pancreatic carcinoma in combination with Chemo and anti-PD-1/KEYTRUDA (Phase 2a).
Team · 8
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biokine.com |
|---|---|
| linkedin.com/company/5550255 | |
| Wikidata | wikidata.org/wiki/Q104480071 |
Identifiers & details
| Legal name | Biokine Therapeutics Ltd. |
|---|---|
| Founded | 2000-7 |
| Employees (exact) | 4 |
| Wikidata QID | Q104480071 |
Acquisitions & public offerings
Acquired by BioLineRx 2018-10
Radar intelligence
Patents
| EPO | 29 |
|---|
Web history (Wayback)
| Domain | biokine.com |
|---|
Wikidata
| QID | Q104480071 |
|---|
Certificate / subdomain footprint
| Subdomains | 6 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512976317 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2000-07-06 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 1 — charge (1) |
| Registered address | אינשטיין 13 נס ציונה |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-06 | סילוק שעבוד |